Dupilumab significantly reduced airway inflammation in patients with uncontrolled, moderate-to-severe type 2 asthma. Read now.

Researchers found increased odds for clinical remission on dupilumab with high blood eosinophil and fractional exhaled nitric ...

Reslizumab may also prove to be efficacious in patients with a similar asthma phenotype. Dual inhibition of IL-4 and IL-13 with dupilumab represents a very promising avenue for biologic-based ...

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch and urticaria activity with dupilumab, according to a poster presented here.

Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also decreasing need for ...

Biologic treatment for atopic dermatitis appeared to improve growth trajectories for younger children, a trial analysis ...

1 Dupilumab Development Program Dupilumab is ... or inhaled corticosteroid medicines; have asthma and use an asthma medicine; or have atopic dermatitis, chronic rhinosinusitis with nasal polyps ...

Discover a proof-of-concept study that was conducted to explore whether dupilumab could induce desensitisation to peanut.

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...